Published in Mediators Inflamm on September 17, 2012
Angiogenic Factors and Cytokines in Diabetic Retinopathy. J Clin Cell Immunol (2013) 1.15
Diabetic Retinopathy: Vascular and Inflammatory Disease. J Diabetes Res (2015) 1.13
Inflammation and pharmacological treatment in diabetic retinopathy. Mediators Inflamm (2013) 1.00
Inflammatory cytokine-specific alterations in retinal endothelial cell function. Microvasc Res (2013) 0.86
Retinal microangiopathy in a mouse model of inducible mural cell loss. Am J Pathol (2014) 0.85
Regulated in development and DNA damage 1 is necessary for hyperglycemia-induced vascular endothelial growth factor expression in the retina of diabetic rodents. J Biol Chem (2014) 0.85
Dendrobium chrysotoxum Lindl. alleviates diabetic retinopathy by preventing retinal inflammation and tight junction protein decrease. J Diabetes Res (2015) 0.82
Elevated Levels of Cytokines Associated with Th2 and Th17 Cells in Vitreous Fluid of Proliferative Diabetic Retinopathy Patients. PLoS One (2015) 0.82
Elevated Serum Levels of Soluble TNF Receptors and Adhesion Molecules Are Associated with Diabetic Retinopathy in Patients with Type-1 Diabetes. Mediators Inflamm (2015) 0.81
Intra-silicone oil injection of methotrexate at the end of vitrectomy for advanced proliferative diabetic retinopathy. Eye (Lond) (2015) 0.81
Ocular Complications of Diabetes and Therapeutic Approaches. Biomed Res Int (2016) 0.80
Serum and vitreous levels of visfatin in patients with diabetic retinopathy. Med Sci Monit (2014) 0.78
RNA sequencing reveals retinal transcriptome changes in STZ‑induced diabetic rats. Mol Med Rep (2016) 0.76
Angiogenin gene polymorphism: A risk factor for diabetic peripheral neuropathy in the northern Chinese Han population. Neural Regen Res (2013) 0.75
Severe prelenticular membrane formation on the surface of a hydrophilic acrylic intraocular lens after cataract surgery in an eye with an Ahmed valve implant. Int J Ophthalmol (2015) 0.75
The significance of the increased expression of phosphorylated MeCP2 in the membranes from patients with proliferative diabetic retinopathy. Sci Rep (2016) 0.75
Association between aqueous humor and vitreous fluid levels of Th17 cell-related cytokines in patients with proliferative diabetic retinopathy. PLoS One (2017) 0.75
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med (1993) 102.56
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med (2008) 38.76
Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ (1998) 32.73
Ranibizumab for neovascular age-related macular degeneration. N Engl J Med (2006) 30.63
Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract (2009) 25.83
Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med (2006) 20.84
IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract (2011) 15.13
The pathobiology of diabetic complications: a unifying mechanism. Diabetes (2005) 14.96
Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med (2010) 10.75
Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology (2006) 9.01
Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol (2004) 6.83
Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet (2007) 6.82
Angiopoietin-2 sensitizes endothelial cells to TNF-alpha and has a crucial role in the induction of inflammation. Nat Med (2006) 5.49
A central role for inflammation in the pathogenesis of diabetic retinopathy. FASEB J (2004) 5.33
VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest (2003) 4.74
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet (2012) 4.46
VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest (2000) 4.36
Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci U S A (1999) 4.05
Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol (2007) 3.93
Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. Am J Pathol (1991) 2.92
Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J (2002) 2.90
Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. Am J Pathol (1995) 2.87
Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science (1996) 2.80
Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology (2006) 2.39
Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci U S A (1996) 2.31
Activation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathy. Nat Med (2009) 2.31
Immunological mechanisms in the pathogenesis of diabetic retinopathy. Semin Immunopathol (2008) 2.26
Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo. Am J Pathol (2002) 2.20
Is diabetic retinopathy an inflammatory disease? Br J Ophthalmol (2002) 2.12
Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. Invest Ophthalmol Vis Sci (2000) 2.05
A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2010) 2.04
Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest (2005) 1.92
VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci (1999) 1.89
Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes (2007) 1.77
Reduction of ischemic damage by application of vascular endothelial growth factor in rat brain after transient ischemia. J Cereb Blood Flow Metab (1998) 1.62
Diabetic retinopathy. Diabetes Care (2003) 1.61
Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. Diabetologia (2009) 1.59
Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol (2002) 1.57
Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications (2001) 1.49
Rho kinase inhibition by fasudil ameliorates diabetes-induced microvascular damage. Diabetes (2008) 1.45
VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2. Invest Ophthalmol Vis Sci (2004) 1.45
Diabetic retinopathy and inflammation: novel therapeutic targets. Middle East Afr J Ophthalmol (2012) 1.35
Patterns of brain angiogenesis after vascular endothelial growth factor administration in vitro and in vivo. Proc Natl Acad Sci U S A (1998) 1.33
Fenofibrate - a potential systemic treatment for diabetic retinopathy? Am J Ophthalmol (2012) 1.31
Vascular endothelial growth factor is up-regulated after status epilepticus and protects against seizure-induced neuronal loss in hippocampus. Neuroscience (2007) 1.23
DIABETIC RETINOPATHY AND RHEUMATOID ARTHRITIS. Lancet (1964) 1.23
AGEs, RAGE, and diabetic retinopathy. Curr Diab Rep (2011) 1.23
Role of intravitreal inflammatory cytokines and angiogenic factors in proliferative diabetic retinopathy. Curr Eye Res (2012) 1.20
Soluble leucocyte adhesion molecules in diabetic retinopathy stimulate retinal capillary endothelial cell migration. Diabetologia (1997) 1.17
C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy. Retina (1998) 1.15
Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina (2001) 1.12
The potential role of PKC beta in diabetic retinopathy and macular edema. Surv Ophthalmol (2002) 1.12
Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci (2001) 1.11
The role of AGEs and AGE inhibitors in diabetic cardiovascular disease. Curr Drug Targets (2005) 1.09
Treatment of diabetic retinopathy with anti-VEGF drugs. Acta Ophthalmol (2010) 1.08
Vascular endothelial cell growth factor-a: not just for endothelial cells anymore. Am J Pathol (2007) 1.07
Protective effects of a coumarin derivative in diabetic rats. Invest Ophthalmol Vis Sci (2009) 1.06
Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. Eur J Ophthalmol (2008) 1.06
Beneficial effects of a novel RAGE inhibitor on early diabetic retinopathy and tactile allodynia. Mol Vis (2011) 1.04
Repeated intravitreal bevacizumab (Avastin(®)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. Acta Ophthalmol (2011) 1.02
Aqueous levels of macrophage migration inhibitory factor and monocyte chemotactic protein-1 in patients with diabetic retinopathy. Diabet Med (2004) 1.01
Angiopoietin concentrations in diabetic retinopathy. Br J Ophthalmol (2005) 1.01
Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction. Biochem J (2012) 1.00
Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies. Eye (Lond) (2011) 0.96
Assessment of selected adhesion molecule and proinflammatory cytokine levels in the vitreous body of patients with type 2 diabetes--role of the inflammatory-immune process in the pathogenesis of proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (2008) 0.96
A potential role for angiopoietin 2 in the regulation of the blood-retinal barrier in diabetic retinopathy. Invest Ophthalmol Vis Sci (2011) 0.95
Vascular adhesion molecules in vitreous from eyes with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci (1999) 0.94
Growth factor alterations in advanced diabetic retinopathy: a possible role of blood retina barrier breakdown. Diabetes (1997) 0.94
Increased lipid peroxide levels and myeloperoxidase activity in the vitreous of patients suffering from proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol (1993) 0.92
Cloricromene, a coumarine derivative, protects against collagen-induced arthritis in Lewis rats. Br J Pharmacol (2000) 0.91
Profile of intraocular tumour necrosis factor-α and interleukin-6 in diabetic subjects with different degrees of diabetic retinopathy. Acta Ophthalmol (2012) 0.91
Proliferative diabetic retinopathy-The influence of diabetes control on the activation of the intraocular molecule system. Diabetes Res Clin Pract (2009) 0.90
Increased expression of periostin in vitreous and fibrovascular membranes obtained from patients with proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci (2011) 0.89
Alterations in stimulus-induced integrin expression in peripheral blood neutrophils of patients with diabetic retinopathy. Am J Med Sci (1997) 0.87
Intercellular adhesion molecule-1 levels in plasma and vitreous from patients with vitreoretinal disorders. Ger J Ophthalmol (1995) 0.87
Human retinal pigment epithelial cell interleukin-8 and monocyte chemotactic protein-1 modulation by T-lymphocyte products. Invest Ophthalmol Vis Sci (1997) 0.85
Simvastatin suppresses expression of angiogenic factors in the retinas of rats with streptozotocin-induced diabetes. Graefes Arch Clin Exp Ophthalmol (2010) 0.85
Potential new medical therapies for diabetic retinopathy: protein kinase C inhibitors. Am J Ophthalmol (2002) 0.84
Soluble cellular adhesion molecules in proliferative vitreoretinopathy and proliferative diabetic retinopathy. Curr Eye Res (1999) 0.82
Suppression of ICAM-1 in retinal and choroidal endothelial cells by plasmid small-interfering RNAs in vivo. Invest Ophthalmol Vis Sci (2009) 0.82
VEGF as a target for neuroprotection. Epilepsy Curr (2008) 0.80
Oral targeting of protein kinase C receptor: promising route for diabetic retinopathy? Curr Drug Deliv (2012) 0.78
Diabetic retinopathy. Curr Ther Endocrinol Metab (1994) 0.78
Rubosixtaurin and other PKC inhibitors in diabetic retinopathy and macular edema. Review. Curr Diabetes Rev (2009) 0.77
Receptor interacting protein kinases mediate retinal detachment-induced photoreceptor necrosis and compensate for inhibition of apoptosis. Proc Natl Acad Sci U S A (2010) 2.20
Low rate of endophthalmitis in a large series of open globe injuries. Am J Ophthalmol (2009) 1.93
Etanercept, a widely used inhibitor of tumor necrosis factor-α (TNF-α), prevents retinal ganglion cell loss in a rat model of glaucoma. PLoS One (2012) 1.35
In vivo evaluation of laser-induced choroidal neovascularization using spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci (2011) 1.14
Tumor necrosis factor-alpha mediates photoreceptor death in a rodent model of retinal detachment. Invest Ophthalmol Vis Sci (2011) 1.02
25-gauge transconjunctival sutureless pars plana vitrectomy for the removal of retained lens fragments and intraocular foreign bodies. Retina (2008) 1.02
Review of the ocular angiogenesis animal models. Semin Ophthalmol (2009) 1.02
Heat shock protein 70 (HSP70) is critical for the photoreceptor stress response after retinal detachment via modulating anti-apoptotic Akt kinase. Am J Pathol (2011) 1.00
Tauroursodeoxycholic acid (TUDCA) protects photoreceptors from cell death after experimental retinal detachment. PLoS One (2011) 0.98
AMP-activated protein kinase suppresses matrix metalloproteinase-9 expression in mouse embryonic fibroblasts. J Biol Chem (2011) 0.97
Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside. Mediators Inflamm (2012) 0.96
Hybrid 25- and 27-Gauge Vitrectomy for Complex Vitreoretinal Surgery. Ophthalmic Surg Lasers Imaging Retina (2016) 0.96
Edaravone, an ROS scavenger, ameliorates photoreceptor cell death after experimental retinal detachment. Invest Ophthalmol Vis Sci (2011) 0.94
Pharmacologic vitreolysis. Semin Ophthalmol (2010) 0.89
Complement involvement in neovascular ocular diseases. Adv Exp Med Biol (2012) 0.88
A novel nonradioactive method to evaluate vascular barrier breakdown and leakage. Invest Ophthalmol Vis Sci (2009) 0.86
Utilizing targeted gene therapy with nanoparticles binding alpha v beta 3 for imaging and treating choroidal neovascularization. PLoS One (2011) 0.81
Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance. Protein Expr Purif (2009) 0.79
Scleral Buckle: Does it Still Have a Role in Retinal Detachment Repair? Int Ophthalmol Clin (2015) 0.76
In vivo high-resolution retinal imaging using adaptive optics. Semin Ophthalmol (2010) 0.76
Sutureless Intrascleral Fixation of Secondary Intraocular Lens Using 27-Gauge Vitrectomy System. Ophthalmic Surg Lasers Imaging Retina (2016) 0.75
Choroidal neovascular membrane formation and retinochoroidopathy in a patient with systemic langerhans cell histiocytosis: a case report and review of the literature. Case Rep Ophthalmol (2012) 0.75
Intraoperative switch to a temporal surgical approach in 23- and 25-gauge microcannula-based sutureless transconjunctival vitrectomy. Open Ophthalmol J (2010) 0.75
PROGRESSIVE RETINAL DETACHMENT IN INFANTS WITH RETINOPATHY OF PREMATURITY TREATED WITH INTRAVITREAL BEVACIZUMAB OR RANIBIZUMAB. Retina (2017) 0.75
Preface. Int Ophthalmol Clin (2004) 0.75
A Novel Approach to Understanding Pathogenesis and Treatment of Capillary Dropout in Retinal Vascular Diseases. Ophthalmic Surg Lasers Imaging Retina (2016) 0.75
Optical Coherence Tomography Angiography of Paracentral Acute Middle Maculopathy Associated With Primary Antiphospholipid Syndrome. Ophthalmic Surg Lasers Imaging Retina (2017) 0.75
Optical coherence tomography appearance of a retinal artery macroaneurysm. Ophthalmic Surg Lasers Imaging (2009) 0.75
Spectral-Domain Optical Coherence Tomography in Older Patients With History of Retinopathy of Prematurity. Ophthalmic Surg Lasers Imaging Retina (2016) 0.75
Case records of the Massachusetts General Hospital. Case 15-2015. A 27-year-old man with a nail in the eye. N Engl J Med (2015) 0.75
HEALTH CONDITIONS LINKED TO AGE-RELATED MACULAR DEGENERATION ASSOCIATED WITH DARK ADAPTATION. Retina (2017) 0.75
Correspondence. Retina (2017) 0.75
SURGICAL MANAGEMENT OF TRACTIONAL RETINOSCHISIS ASSOCIATED WITH VITREOUS HEMORRHAGE IN RETINOPATHY OF PREMATURITY. Retin Cases Brief Rep (2017) 0.75
Posterior nodular scleritis. JAMA Ophthalmol (2015) 0.75
Optical Coherence Tomography Angiography Findings in Punctate Inner Choroidopathy. Ophthalmic Surg Lasers Imaging Retina (2017) 0.75
Repair of Total Tractional Retinal Detachment in Norrie Disease: Report of Technique and Successful Surgical Outcome. Ophthalmic Surg Lasers Imaging Retina (2017) 0.75
A New Variant of Polypoidal Choroidal Vasculopathy With Annular Pigmentary Changes in Haitian Males. Ophthalmic Surg Lasers Imaging Retina (2016) 0.75